Syracuse

Plasmodium fakiparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014

Archive ouverte

Fall, Bécaye | Madamet, Marylin | Camara, Cheikhou | Amalvict, Rémy | Fall, Mansour | Nakoulima, Aminata | Diatta, Bakary | Diemé, Yaya | Wade, Boubacar | Pradines, Bruno

Edité par CCSD ; Centers for Disease Control and Prevention -

International audience. We successfully cultured 36 Plasmodium falciparum isolates from blood samples of 44 malaria patients admitted to the Hopital Principal de Dakar (Dakar, Senegal) during August December 2014. The prevalence of isolates with in vitro reduced susceptibility was 30.6% for monodesethylamodiaquine, 52.8% for chloroquine, 44.1% for mefloquine, 16.7% for doxycycline, 11.8% for piperaquine, 8.3% for artesunate, 5.9% for pyronaridine, 2.8% for quinine and dihydroartemisinin, and 0.0% for lumefantrine. The prevalence of isolates with reduced in vitro susceptibility to the artemisinin-based combination therapy partner monodesethylamodiaquine increased from 5.6% in 2013 to 30.6% in 2014. Because of the increased prevalence of P. falciparum parasites with impaired in vitro susceptibility to monodesethylamodiaquine, the implementation of in vitro and in vivo surveillance of all artemisinin-based combination therapy partners is warranted.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion